IAVI at the 2024 ASTMH Annual Meeting

On Nov. 13-17, IAVI will attend the American Society of Tropical Medicine and Hygiene’s (ASTMH) 2024 Annual Meeting — also known as TropMed. Experts in emerging infectious diseases (EIDs), neglected diseases, and global health will assemble in New Orleans, Louisiana, U.S., to share the latest advances from across the field. IAVI looks forward to spotlighting our growing EIDs portfolio at this event, including our Lassa fever, Marburg virus, and Sudan ebolavirus vesicular stomatitis virus (VSV)-based vaccine candidates. Join us for the following sessions:

An IAVI-organized symposium on our progress toward a Lassa fever vaccine.    

• End-to-End Development of a Lassa Fever Vaccine Program will provide a robust overview of IAVI’s Lassa fever vaccine candidate and outline a partnership-based model that future vaccine developers may draw upon when establishing novel programs. This session will be co-chaired by Swati Gupta, vice president and head of EIDs and epidemiology, IAVI, and Melanie McCauley, clinical research liaison for West Africa, Walter Reed Army Institute of Research (WRAIR). Speakers include: Christian Happi, professor of molecular biology and genomics, Redeemer’s University; Kent Kester, executive director of vaccine research and development, Coalition for Epidemic Preparedness Innovations (CEPI); Christopher Cooper, director, viral vaccines, IAVI’s Vaccine Design and Development Lab (DDL); Mark Kieh, research scientist, The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL); and Johan Vekemans, senior science and clinical advisor, IAVI. — November 14 at 5:15pm CST

A timely Marburg virus vaccine development talk from the DDL.

• Christopher Cooper, director, viral vaccines, IAVI DDL, will deliver an oral abstract on Protective Vaccination of Nonhuman Primates against Aerosol Exposure to Marburg Virus using a Vesicular Stomatitis Virus-vectored Vaccine: Implications for Mucosal Vaccine Strategies and Unpredictable Filovirus Transmission in a session covering viruses and immunology. — November 14 at 9:15am CST

Ten IAVI and partner posters.

Topics include:

• Safety and immunogenicity data from the first-in-human Phase 1 clinical trial of IAVI’s Lassa fever vaccine candidate (IAVI C102)
• Updated data from a Phase 1 trial of IAVI’s VSV-Sudan ebolavirus vaccine candidate
• Findings from IAVI X100, the largest study of Lassa fever virus incidence in Sierra Leone
• Vaccine confidence and the importance of community engagement to Lassa fever vaccine trials in West Africa
• Prevalence of filovirus antibodies among sub-Saharan African populations
• Challenges and prospects for assessing the immunogenicity of filovirus vaccines

Keep an eye on our LinkedIn and Instagram feeds for live updates during the conference. The full calendar of IAVI’s presence at TropMed 2024 is now live. We hope to see you on site in New Orleans.